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Abstract
Background: Airway colonization of mechanically ventilated very low birth weight infants (birth
weight < 1500 grams) by Ureaplasma urealyticum (Uu) is associated with an increased risk of
bronchopulmonary dysplasia (BPD). While Uu is sensitive to erythromycin in vitro, the efficacy of
intravenous (IV) erythromycin to eliminate Uu from the airways has not been studied.
Methods: 17 very low birth weight infants with Uu positive tracheal aspirate (TA) cultures were
randomized to either 5 (8 infants) or 10 days (9 infants) of IV erythromycin lactobionate (40 mg/
kg/day in 3 divided doses). Tracheal aspirate cultures for Uu were performed on days 0, 5, 10 and
15.
Results: Intravenous erythromycin failed to eliminate airway colonization in a large proportion of
infants regardless of whether they received 5 or 10 days of treatment. Ureaplasma urealyticum was
isolated from 4/15 (27%) of TAs obtained at 5 days, 5/12 TAs (42%) obtained at 10 days and 6/
11(55%) TAs obtained at 15 days (combined group data).
Conclusions: Erythromycin administered IV does not eliminate Uu from the airways in a large
proportion of infants. Failure of erythromycin to eliminate Uu from the airways may contribute to
the lack of efficacy of this drug in reducing the incidence of BPD in very low birth weight infants.
Background
Airway colonization or infection with Ureaplasma urealyti-
cum (Uu) has been associated with an increased inflam-
matory response and subsequent development of chronic
lung disease in mechanically ventilated very low birth
weight infants [1–6]. Eradication of these organisms
could potentially reduce lung injury and reduce the inci-
dence of chronic lung disease. While most Uu isolates are
sensitive to macrolide antibiotics in vitro, the clinical effi-
cacy of erythromycin to clear these organisms from the
respiratory tract has not been documented extensively
[5,7–9]. Treatment of Uu infections with erythromycin in
mechanically ventilated very low birth weight infants has
failed to reduce the incidence of chronic lung disease [10–
12]. The lack of effect of erythromycin on the incidence of
chronic lung disease may be a result of failure to eliminate
Uu from the lung. In order to address these questions, we
designed a pilot study to examine the efficacy of either a 5
or 10 day course of intravenous erythromycin to eradicate
Uu from the airways of very low birth weight infants.
Methods
The study population consisted of 17 very low birth
weight (VLBW) infants admitted to the neonatal intensive
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care unit (NICU) at the Louisiana State University Health
Sciences Center (LSUHSC) in Shreveport between May
1998 and July 2001. We designed a randomized, prospec-
tive, non-blinded evaluation of the efficacy of 5 versus 10
days of intravenous (IV) erythromycin lactobionate to
eradicate Uu from the airways of mechanically ventilated
VLBW infants. Mechanically ventilated VLBW infants were
cultured for Uu in the airways (screening TA culture) at
the discretion of the attending neonatologists. Infants
who were still intubated and whose physician decided to
treat with erythromycin were eligible for study. Infants
were excluded from the study if they were moribund and
not expected to survive, or if consent to participate was
refused by the parents.
Randomization was performed by the use of sealed enve-
lopes with the allocation of patients to either a 5 day or 10
day course of intravenous erythromycin lactobionate (40
mg/kg/day). Randomization strategy utilized blocks of
10, with 5 cards assigned to each treatment group. There
was no stratification by weight or gestation. Tracheal aspi-
rates were cultured for the presence of Uu on the day that
treatment was initiated (Day 0) and on the 5th, 10th and
15th day thereafter if the infant remained intubated. The
study was approved by the Institutional Review Board for
Human Research at LSUHSC-Shreveport.
Tracheal aspirates were collected, transported to the lab
and cultured for Uu on the same day. Fifty microliters of
tracheal aspirate was placed in 2 ml of SP4 with urea
(Remel, Lexana, KS), urea enriched PPLO broths and
Mycotrim GU® biphasic culture system (Irvine Scientific,
Santa Anna, CA) [13]. The media was inspected twice per
day for the first 2 days, and then inspected daily for 5 days
to observe any color change in the media indicative of a
positive culture. The presence of Uu was determined by
color change in the broth and microscopic observation of
characteristic colony morphology. Follow up cultures
were performed using SP4 with urea and urea enriched
PPLO broths.
The primary endpoint of this study was the eradication of
Uu from the airways of the infant. Originally it was
planned to study 30 infants (15 patients in each group).
The study was terminated early when it became apparent
that there was an unacceptably high incidence of treat-
ment failure in both groups. Infants were followed
through their initial hospitalization and information on
respiratory outcomes was collected.
Statistical analysis was performed using the SPSS for Win-
dows version 6.0 (SPSS Inc., Chicago, IL). Fisher's Exact
test was used to assess the statistical differences in categor-
ical variables. The Mann-Whitney U test was used to assess
significance of continuous variables. A probability value
of less than 0.05 was considered statistically significant.
The data are presented as median and (range).
Results
There were 17 infants enrolled in the study. Nine patients
received 10 days of treatment and 8 patients received 5
days. Patients were enrolled in the study at 7 (2–33) days.
The clinical characteristics of the patients are shown in
Table 1. There were no differences in birth weight, gesta-
tional age, pre and post-natal steroid exposure or age of
enrollment in the study between infants who were treated
for 5 days as compared to those treated for 10 days (Table
2). One infant (randomized to receive 5 days of erythro-
mycin) had a Day 0 TA culture that was negative for Uu.
Erythromycin failed to eradicate Uu from the airways in a
significant proportion of infants who were treated for
either 5 or 10 days (Table 3). There were no significant dif-
ferences in the proportion of infants in whom Uu was
successfully eliminated from the airways between those
who were treated for 5 days compared to 10 days. Overall,
6 of the 11 (55%) infants who were re-cultured after 14
days had positive airway cultures for Uu. The pattern of
positive Uu cultures varied considerably from patient to
patient. Some patients cleared the Uu while on erythro-
mycin only to have positive cultures once treatment was
stopped. Others were persistently positive for Uu through-
out the study, while others cleared after a period of treat-
ment with erythromycin and remained free of Uu.
Infants who had persistent airway colonization with Ure-
aplasma urealyticum after completion of erythromycin
therapy had increased duration of mechanical ventilation
(42 (24–73) vs. 24 (9–52) days; p = 0.035) and increased
duration of oxygen dependency (106 (44–200) vs. 41
(13–97) days; p = 0.016). There was a trend towards an
increased incidence of chronic lung disease in infants with
persistent Ureaplasma in the airways (Figure 1).
Table 1: Clinical Characteristics of Subjects (All Patients) N = 17
Gestation (weeks) 25 (23–29)
Birth Weight (grams) 777 (620–1160)
Histological Chorioamnionitis* 6/11 (55)
Prenatal Steroids 11/17 (65)
RDS 16/17 (94)
Surfactant Therapy 16/17 (94)
Postnatal Steroids 15/17 (88)
Duration Oxygen Therapy (days) 64 ± 4
Duration Mechanical Ventilation (days) 31 ± 4
Oxygen at 28 days 13/17 (77)
Oxygen at 36 weeks PCA 4/17 (24)
IVH 4/17 (24)
Data are presented as Median (range). Numbers in parenthesis are 
percentages RDS Respiratory Distress Syndrome IVH Intraventricular 
hemorrhage PCA Postconceptional age *Not all patients had 
pathological examination of the placentaBMC Pediatrics 2003, 3 http://www.biomedcentral.com/1471-2431/3/10
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Discussion
Colonization and/or infection with Uu have been associ-
ated with an increased risk of developing chronic lung dis-
ease in several studies [1–4]. Because this finding has not
been confirmed by other studies, the causal link between
Uu and chronic lung disease remains controversial.
Despite this controversy, more than 50% of neonatolo-
gists surveyed indicated they would provide antibiotic
therapy to preterm infants with respiratory disease who
had Uu positive tracheal (or even pharyngeal) cultures
[14]. The decision to culture infants and whether to treat
positive cultures were made by the attending physicians
based on the clinical situation. Thus not all VLBW infants
were cultured and not all infants with positive cultures
were treated. This selection bias may influence the inter-
pretation of the results as the tendency is to treat smaller,
sicker infants. However, the purpose of this study was not
to determine if treatment prevents the development of
BPD but to assess if erythromycin treatment could eradi-
cate Uu from the airways. This is particularly relevant in
view of the recent report correlating persistence of Uu
with the development of chronic lung disease. [15]. In the
11 infants who remained intubated for repeat cultures,
54% were still positive. Because of this finding, we
believed that continued exposure of infants to the
toxicities and risks of the trial were not warranted. This
obviously limits many of the conclusions that could be
drawn. It is possible that erythromycin therapy may be
more efficacious than is presented in this small study.
However, we do believe that the real failure rate of eryth-
romycin is too high for it to be useful in this setting.
Clinical isolates of Uu are susceptible to macrolide antibi-
otics, tetracyclines, quinolones and chloramphenicol
[5,7–9]. Erythromycin, a macrolide antibiotic, has been
suggested as the drug of choice to treat neonatal Uu infec-
tions due to unacceptable side effects of the other poten-
tial agents [5]. Four clinical studies (2 randomized
controlled trials) have evaluated the use of erythromycin
to treat Uu infected/colonized infants of which 2 of the
studies evaluated microbiological outcome [10–12,16].
Treatment with erythromycin did not affect the incidence
of chronic lung disease in any of these trials. In our study,
intravenous erythromycin lactobionate (40 mg/kg/day)
failed to eradicate Uu in greater than 50% of colonized
very low birth weight infants. This contrasts with the find-
ing of two earlier studies in which erythromycin elimi-
nated Uu colonization in 15/19 (79%) and 12/14 (86%)
infants treated [11,16]. There are several potential reasons
that might explain the differences observed. In the study
reported by Bowman, the timing of repeat cultures was
not defined [16]. It is possible that follow up cultures were
taken shortly after completing therapy when residual
erythromycin may have suppressed the growth of Uu. This
Table 2: Clinical Characteristics of Subjects
5 days n = 8 10 days n = 9 p
Birth weight 810 (775–965) 720 (620–1160) 0.177
Gestation 25 (24–29) 25 (23–28) 0.921
ROM (hours) 5.25 (0–70) 30 (0–504) 0.514
Prenatal Steroids 5 (63) 6 (66) 1.000
Histologic Chorioamnionitis* 1 (33) 5 (55) 0.545
Age at Enrollment 8 (3–11) 7 (2–33) 0.529
Surfactant therapy 8 (100) 8 (88) 1.000
Postnatal Steroids 6 (75) 9 (100) 0.206
Data are presented as Median (range). Numbers in parenthesis are percentages *Not all patients had pathological examination of the placenta
Table 3: Follow Up TA Cultures for Ureaplasma urealyticum
Percent Positive Uu
Group Day 0 Day 5 Day 10 Day 15
5 Days (n = 8) 7/8 (88%)* 3/7 (43%) 3/4 (75%) 3/4 (75%)
10 Days (n = 9) 9/9 (100%) 1/8 (13%) 2/8 (25%) 3/7 (43%)
All patients 16/17 (94%) 4/15 (27%) 5/12 (42%) 6/10 (55%)
* One infant who a positive screening culture for Ureaplasma urealyticum had a negative culture on Day 0 when starting therapy. A follow up 
culture on Day 5 again was positive for Uu.BMC Pediatrics 2003, 3 http://www.biomedcentral.com/1471-2431/3/10
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is not likely in Jonsson's study in which follow up cultures
were performed a week after completing therapy [11]. We
utilized a similar or higher dose of erythromycin com-
pared to the previous studies, making drug dose an
unlikely factor in the failure of erythromycin to eliminate
Uu.
Isolation of Uu with resistance or intermediate sensitivity
to erythromycin has been reported [8,9,17]. Depending
on the methodology employed, the rate of intermediate
sensitivities (MIC 1 – 4 µg/ml) to erythromycin may be as
high as 100% [9]. Peak serum concentrations of erythro-
mycin following 40 mg/kg/day intravenous dosing are
approximately 3.4 µg/ml [18]. Although data in neonates
are lacking, erythromycin concentrations in bronchial
secretions are less than 25% of serum concentrations in
adults [19]. Therefore the local concentration of erythro-
mycin in the airways/lung may not be sufficient to eradi-
cate Uu with intermediate antibiotic sensitivities. We did
not measure erythromycin sensitivities in our isolates.
Anti-microbial treatment of Uu colonization or infection
has not proven successful in preventing the development
of chronic lung disease. We believe the high failure rate of
IV erythromycin in eliminating Uu from the airway that
we observed in this study may underlie the failure of
erythromycin therapy to reduce the incidence of chronic
lung disease. In our study, infants who failed to clear Uu
were ventilated longer and were at increased risk of
chronic lung disease, suggesting a role for prolonged
infection or colonization with adverse outcome.
In summary we found that treatment of Uu colonization
with intravenous erythromycin was associated with a high
failure rate in our NICU population. Treatment strategies
with other agents may be required to eliminate Uu from
the airways of colonized preterm infants in order to min-
imize the incidence of chronic lung disease.
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